eli lilly glp-1 supply news today is selling $12.9 billion of drugs every three months — and expects to sell even more FDA approves Eli Lilly's GLP-1

Top Research Studies on GLP-1s and Cardiovascular Outcomes The November 2023 issue of The New England Journal of Medicine shared results from a research study (SELECT) involving 17,000 patients that showed the use of semaglutide was linked to a 20% reduction in the risk of major adverse cardiovascular events such as heart disease, stroke and peripheral arterial disease in patients who had previously been diagnosed with heart disease

10.1172/JCI176345 87 MahalingamS.BellamkondaR.ArumugamM

Its important to remember that semaglutide GLP-1 is not a magic solution, but a tool to be incorporated into a broader strategy involving a healthy diet and regular physical exercise for the best results

DNA was isolated, using a DNeasy kit (Qiagen), from fecal samples as well as from cecum, intestinal fluid, and intestinal wall scrapings